Hazte socio de la SAMFyC

Última publicación SAMFyC: Actualización en MF y APS

 

AULA VIRTUAL SAMFyC

Aula de formación virtual de SAMFyC

SAMFyC CONGRESOS

Historico de Comunicaciones
presentadas a los Congresos
Andaluces de MFyC (SAMFyC), desde 2008.


* * * * * * * * * * * * * * * * * * * * * * * * *

Información Socios

Ofertas de Trabajo
Ofertas de Trabajo SOCIOS SAMFYC

¡Actualiza tus datos!
Actualiza tus datos

 

Buscador de Contenidos

Sociedades Federadas

Medicina Familiar y Comunitaria

Sociedades Científicas de Medicina Familiar y Comunitaria

Enlaces de Interés

Consulte Nuestros Enlaces.
Enlaces de Interés

Acceso Socios



Buscador de publicaciones externas y alertas bibliográficas

Mayo 2013 PDF Imprimir E-mail
Miércoles, 05 de Junio de 2013 00:00

Volver

SELECCIÓN DE REFERENCIAS BIBLIOGRÁFICAS DE LO PUBLICADO EN RELACIÓN CON ATENCIÓN PRIMARIA
Selección realizada por Antonio Manteca González
 
 
Raman G, Moorthy D, Hadar N, Dahabreh IJ, O'Donnell TF, Thaler DE, et al. Management strategies for asymptomatic carotid stenosis: a systematic review and meta-analysis. Ann Intern Med. 2013; 158:676-685 [M,II]
23648949             R/C
ESTRATEGIAS DE MANEJO DE LA ESTENOSIS CAROTÍDEA ASINTOMÁTICA: REVISIÓN SISTEMÁTICA Y METAANÁLISIS
 
Moyer VA; U.S. Preventive Services Task Force*. Vitamin D and calcium supplementation to prevent fractures in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013; 158:691-696 [M,III]
23440163             R/C
SUPLEMENTOS DE CALCIO Y VITAMINA D PARA PREVENIR FRACTURAS EN ADULTOS: DECLARACIÓN DE RECOMENDACIÓN DEL US PREVENTIVE SERVICES TASK FORCE
 
Nestle M, Nesheim MC. To supplement or not to supplement: the U.S. Preventive Services Task Force recommendations on calcium and vitamin D. Ann Intern Med. 2013; 158:701-702 [M,III]
SUPLEMENTAR O NO SUPLEMENTAR: RECOMENDACIONES DEL US PREVENTICE SERVICES TASK FORCE SOBRE EL CALCIO Y LA VITAMINA D
 
Kao D, Bucher Bartelson B, Khatri V, Dart R, Mehler PS, Katz D, et al. Trends in reporting methadone-associated cardiac arrhythmia, 1997-2011: an analysis of registry data. Ann Intern Med. 2013; 158:735-740 [T,II]
23689766             R/C
TENDENCIAS EN LOS INFORMES SOBRE ARRITMIA CARDIACA ASOCIADA A METADONA, 1997-2011: ANÁLISIS DE DATOS DE LOS REGISTROS
 
O'Connor E, Gaynes BN, Burda BU, Soh C, Whitlock EP. Screening for and treatment of suicide risk relevant to primary care: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2013; 158:741-754 [M,II]
23609101             R/C
CRIBAJE Y TRATAMIENTO DEL RIESGO RELEVANTE DE SUICIDIO EN ATENCIÓN PRIMARIA: REVISIÓN SISTEMÁTICA PARA EL US PREVENTIVE SERVICES TASK FORCE
 
Qaseem A, Barry MJ, Denberg TD, Owens DK, Shekelle P; Clinical Guidelines Committee of the American College of Physicians*. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med. 2013; 158:761-769 [M,III]
23567643             R/C
CRIBAJE DEL CÁNCER DE PRÓSTATA: DECLARACIÓN DE ORIENTACIÓN DEL COMITÉ DE GUÍAS CLÍNICAS DEL AMERICAN COLLEGE OF PHYSICIANS
 
Repetto L, Abbatecola AM, Paolisso G. "The older, the wiser" in prostate cancer treatment choices? Ann Intern Med. 2013; 158:772-773 [AO,I]
¿"LO MÁS ANTIGUO, LO MÁS SABIO" EN LAS ELECCIONES DE TRATAMIENTO DEL CÁNCER DE PRÓSTATA?
 
 
Fernández-Liz E ¿Cómo revisar la medicación en los pacientes pluripatológicos? Aten Primaria. 2013; 45:233-234 [AO,I]
¿CÓMO REVISAR LA MEDICACIÓN EN LOS PACIENTES PLURIPATOLÓGICOS?
 
Galván-Banqueri M, González-Méndez AI, Alfaro-Lara ER, Nieto-Martín MD, Pérez-Guerrero C, Santos-Ramos B. Evaluación de la adecuación del tratamiento farmacológico en pacientes pluripatológicos. Aten Primaria. 2013; 45:235-243 [T,I]
23337466             R/C
EVALUACIÓN DE LA ADECUACIÓN DEL TRATAMIENTO FARMACOLÓGICO EN PACIENTES PLURIPATOLÓGICOS
 
Brenes FJ, Cozar JM, Esteban M, Fernández-Pro A, Molero JM. Criterios de derivación en incontinencia urinaria para atención primaria. Aten Primaria. 2013; 45:263-273 [R,II]
23623519             R/C
CRITERIOS DE DERIVACIÓN EN INCONTINENCIA URINARIA PARA ATENCIÓN PRIMARIA
 
Segura A, Giner V. El consumo sanitario inapropiado y la trivialización de la medicina. Aten Primaria. 2013; 45:274-277 [AO,II]
23218832             R/C
EL CONSUMO SANITARIO INAPROPIADO Y LA TRIVIALIZACIÓN DE LA MEDICINA
 
 
Baldwin DS, Foong T. Antidepressant drugs and sexual dysfunction. Br J Psychiatry. 2013; 202:396-397 [AO,I]
23732933             R/C
ANTIDEPRESIVOS Y DISFUNCIÓN SEXUAL
 
Rajyaguru P, Cooper M. Role of dietary supplementation in attention-deficit hyperactivity disorder. Br J Psychiatry. 2013; 202:398-399 [AO,I]
23732934             R/C
PAPEL DE LOS SUPLEMENTOS DIETÉTICOS EN EL TRASTORNO DE HIPERACTIVIDAD Y DÉFICIT DE ATENCIÓN
 
Strech D, Mertz M, Knüppel H, Neitzke G, Schmidhuber M. The full spectrum of ethical issues in dementia care: systematic qualitative review. Br J Psychiatry. 2013; 202:400-406 [M,II]
23732935             R/C
ESPECTRO COMPLETO DE ASPECTOS ÉTICOS DE LA ATENCIÓN A LA DEMENCIA: REVISIÓN SISTEMÁTICA CUALITATIVA
 
 
Reid IC. Are antidepressants overprescribed? No. BMJ. 2013; 346:f190 [AO,I]
¿SE PRESCRIBEN EN EXCESO LOS ANTIDEPRESIVOS?NO
 
Spence D. Are antidepressants overprescribed? Yes. BMJ. 2013; 346:f191 [AO,I]
¿SE PRESCRIBEN EN EXCESO LOS ANTIDEPRESIVOS?
 
Vickers AJ, Ulmert D, Sjoberg DD, Bennette CJ, Björk T, Gerdtsson A, et al. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. BMJ. 2013; 346:f2023 [CC,II]
23596126             R/C
ESTRATEGIA PARA LA DETECCIÓN DEL CÁNCER DE PRÓSTATA BASADA EN LA RELACIÓN ENTRE EL PSA A LOS 40-55 AÑOS DE EDAD Y EL RIESGO DE METÁSTASIS A LARGO PLAZO: ESTUDIO DE CASO-CONTROL
 
Toren P, Margel D, Kulkarni G, Finelli A, Zlotta A, Fleshner N. Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study. BMJ. 2013; 346:f2109 [EC,I]
23587564             R/C
EFECTO DEL DUTASTERIDE SOBRE LA PROGRESIÓN CLÍNICA DE LA HIPERPLASIA BENIGNA DE PRÓSTATA EN HOMBRES ASINTOMÁTICOS CON PRÓSTATA AGRANDADA: ANÁLISIS POST HOC DEL ESTUDIO REDUCE
 
Eurich DT, Simpson S, Senthilselvan A, Asche CV, Sandhu-Minhas JK, McAlister FA. Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study. BMJ. 2013; 346:f2267 [S,II]
23618722             R/C
SEGURIDAD Y EFECTIVIDAD COMPARADAS DE LA SITAGLIPTINA EN PACIENTES CON DIABETES TIPO 2: ESTUDIO RETROSPECTIVO DE COHORTE POBLACIONAL
 
Mathews JD, Forsythe AV, Brady Z, Butler MW, Goergen SK, Byrnes GB, et al. Cancer risk in 680 000 people exposed to computed tomography scans in childhood or adolescence: data linkage study of 11 million Australians. BMJ. 2013; 346:f2360 ,[S,II]
23694687             R/C
RIESGO DE CÁNCER EN 680.000 PERSONAS EXPUESTAS A TAC EN LA NIÑEZ Y ADOLESCENCIA: ESTUDIO DE DATOS ENLAZADOS DE 11 MILLONES DE AUSTRALIANOS
 
Lavigne E, Holowaty EJ, Pan SY, Villeneuve PJ, Johnson KC, Fergusson DA, et al. Breast cancer detection and survival among women with cosmetic breast implants: systematic review and meta-analysis of observational studies. BMJ. 2013; 346:f2399 [M,II]
23637132             R/C
DETECCIÓN DE CÁNCER DE MAMA Y SUPERVIVENCIA ENTRE MUJERES CON IMPLANTES DE MAMA COSMÉTICOS: REVISIÓN SISTEMÁTICA Y METAANÁLISIS DE ESTUDIOS OBSERVACIONALES
 
van Vugt SF, Broekhuizen BD, Lammens C, Zuithoff NP, de Jong PA, Coenen S, et al; GRACE consortium. Use of serum C reactive protein and procalcitonin concentrations in addition to symptoms and signs to predict pneumonia in patients presenting to primary care with acute cough: diagnostic study. BMJ. 2013; 346:f2450 [T,I]
23633005             R/C
USO DE LAS CONCENTRACIONES DE PCR SÉRICO Y PROCALCITONINA ADEMÁS DE LOS SÍNTOMAS Y SIGNOS PARA PREDECIR NEUMONÍA EN PACIENTES QUE ACUDEN CON TOS A LA ATENCIÓN PRIMARIA: ESTUDIO DIAGNÓSTICO
 
Schouten HJ, Geersing GJ, Koek HL, Zuithoff NP, Janssen KJ, Douma RA, et al. Diagnostic accuracy of conventional or age adjusted D-dimer cut-off values in older patients with suspected venous thromboembolism: systematic review and meta-analysis. BMJ. 2013; 346:f2492 [M,II]
23645857             R/C
EXACTITUD DIAGNÓSTICA DE LOS VALORES DE CORTE DEL DÍMERO D, TANTO CONVENCIONAL COMO AJUSTADO A LA EDAD, EN PACIENTES MAYORES CON SOSPECHA DE TROMBOEMBOLISMO VENOSO: REVISIÓN SISTEMÁTICA Y METAANÁLISIS
 
Edmiston R, Mitchell C. Hearing loss in adults. BMJ. 2013; 346:f2496 [R,I]
PÉRDIDA DE AUDICIÓN EN ADULTOS
 
Roland M, Paddison C. Better management of patients with multimorbidity. BMJ. 2013; 346:f2510 [AO,I]
UN MEJOR MANEJO DE LOS PACIENTES CON PLURIMORBILIDAD
 
Pilling S, Mayo-Wilson E, Mavranezouli I, Kew K, Taylor C, Clark DM; Guideline Development Group. Recognition, assessment and treatment of social anxiety disorder: summary of NICE guidance. BMJ. 2013; 346:f2541 [M,II]
RECONOCIMIENTO, VALORACIÓN Y TRATAMIENTO DEL TRASTORNO DE ANSIEDAD SOCIAL: RESUMEN DE LA GUÍA NICE
 
Hippisley-Cox J, Coupland C, Brindle P. Derivation and validation of QStroke score for predicting risk of ischaemic stroke in primary care and comparison with other risk scores: a prospective open cohort study. BMJ. 2013; 346:f2573 [M,II]
23641033             R/C
DERIVACIÓN Y VALIDACIÓN DE LA TABLA QSCORE PARA PREDECIR EL RIESGO DE ICTUS ISQUÉMICO EN ATENCIÓN PRIMARIA Y COMPARACIÓN CON OTRAS TABLAS DE RIESGO: ESTUDIO DE COHORTE PROSPECTIVA ABIERTA
 
Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes among patients treated with statins: population based study. BMJ. 2013; 346:f2610 [S,II]
23704171             R/C
RIESGO DE INCIDENCIA DE DIABETES ENTRE PACIENTES TRATADOS CON ESTATINAS: ESTUDIO POBLACIONAL
 
Dawson AL, Dellavalle RP. Acne vulgaris. BMJ. 2013; 346:f2634 [R,I]
ACNÉ VULGAR
 
Dennis J, Ramsay T, Turgeon AF, Zarychanski R. Helmet legislation and admissions to hospital for cycling related head injuries in Canadian provinces and territories: interrupted time series analysis. BMJ. 2013; 346:f2674 [T,I]
23674137             R/C
LEGISLACIÓN SOBRE EL CASCO E INGRESOS EN EL HOSPITAL POR HERIDAS EN LA CABEZA RELACIONADAS CON EL CICLISMO EN LAS PROVINCIAS Y TERRITORIOS DE CANADÁ: ANÁLISIS DE SERIE TEMPORAL INTERRUMPIDA
 
Bird J, Biggs T, Thomas M, Salib R. Adult acute rhinosinusitis. BMJ. 2013; 346:f2687 [R,I]
RINOSINUSITIS AGUDA EN EL ADULTO
 
Stone S, Kontowski G, Gallagher R, Storr J, Teare L. Keeping hand hygiene high on the patient safety agenda. BMJ. 2013; 346:f2699 [AO,I]
MANTENER LA HIGIENE DE MANOS EN LO ALTO DE LOS PLANES DE SEGURIDAD DEL PACIENTE
 
Moynihan R. The future of medicine lies in truly shared decision making. BMJ. 2013; 346:f2789 [AO,I]
EL FUTURO DE LA MEDICINA DESCANSA SOBRE LA VERDADERA TOMA DE DECISIONES COMPARTIDA
 
Tiefer L, Witczak K, Heath I. A call to challenge the "Selling of Sickness". BMJ. 2013; 346:f2809 [AO,II]
LLAMAMIENTO A DESAFIAR A LA "VENTA DE ENFERMEDADES"
 
Fields E, Chard J, Murphy MS, Richardson M; on behalf of the Guideline Development Group and technical team. Assessment and initial management of feverish illness in children younger than 5 years: summary of updated NICE guidance. BMJ. 2013; 346:f2866 [M,II]
VALORACIÓN Y TRATAMIENTO INICIAL DE LA ENFERMEDAD FEBRIL EN LOS NIÑOS DE MENOS DE 5 AÑOS: RESUMEN DE LA GUÍA NICE ACTUALIZADO
 
Davies E. Will MOOCs transform medicine? BMJ. 2013; 346:f2877 [AO,I]
¿VAN A TRANSFORMAR LA MEDICINA LOS MOOC?
 
Kennedy A, Bower P, Reeves D, Blakeman T, Bowen R, Chew-Graham C, et al; Salford National Institute for Health Research Gastrointestinal programme Grant Research Group. Implementation of self management support for long term conditions in routine primary care settings: cluster randomised controlled trial. BMJ. 2013; 346:f2882 [EC,II]
23670660             R/C
PUESTA EN MARCHA DE LA AYUDA EN EL AUTOMANEJO DE ENFERMEDADES DE LARGA DURACIÓN EN LOS DISPOSITIVOS HABITUALES DE ATENCIÓN PRIMARIA: ENSAYO CONTROLADO ALEATORIZADO AGRUPADO
 
Sugarman J. Implications of universal screening for HIV infection. BMJ. 2013; 346:f2957 [AO,I]
IMPLICACIONES DEL CRIBAJE UNIVERSAL DE LA INFECCIÓN POR VIH
 
Maffulli N. Autologous blood products in musculoskeletal medicine. BMJ. 2013; 346:f2979 [AO,I]
PRODUCTOS AUTÓLOGOS DE LA SANGRE EN LA MEDICINA OSTEOMUSCULAR
 
McKinstry B, Hanley J, Wild S, Pagliari C, Paterson M, Lewis S et al. Telemonitoring based service redesign for the management of uncontrolled hypertension: multicentre randomised controlled trial. BMJ. 2013; 346:f3030 [EC,I]
                               R/C
REDISEÑO DEL SERVICIO BASADO EN LA TELEMONITORIZACIÓN PARA EL MANEJO DE LA HIPERTENSIÓN NO CONTROLADA: ENSAYO CONTROLADO ALEATORIZADO MULTICÉNTRICO
 
Segal J. Should we be reassured about sitagliptin? BMJ. 2013; 346:f3051 [AO,I]
¿DEBERÍAMOS REASEGURARNOS RESPECTO A LA SITAGLIPTINA?
 
Sodickson A. CT radiation risks coming into clearer focus. BMJ. 2013; 346:f3102 [AO,I]
TRAER LOS RIESGOS DE LA RADIACIÓN POR TAC A LA CLARIDAD DE LOS FOCOS
 
McCartney M. Antibiotics for back pain: hope or hype? BMJ. 2013; 346:f3122 [AO,I]
ANTIBIÓTICOS PARA EL DOLOR DE ESPALDA: ¿ESPERANZA O EXAGERACIÓN?
 
Gupta K, Trautner BW. Diagnosis and management of recurrent urinary tract
infections in non-pregnant women. BMJ. 2013; 346:f3140 [R,I]
DIANÓSTICO Y MANEJO DE LAS INFECCIONES RECURRENTES DE VÍAS URINARIAS EN MUJERES NO EMBARAZADAS
 
Huupponen R, Viikari J. Statins and the risk of developing diabetes. BMJ. 2013; 346:f3156 [AO,I]
ESTATINAS Y RIESGO DE DESARROLLAR DIABETES
 
D'Souza S, Guptha S. Preventing admission of older people to hospital. BMJ. 2013; 346:f3186 [AO,I]
PREVENIR EL INGRESO DE LOS ANCIANOS EN EL HOSPITAL
 
Sedgwick P. Statistical question: P values or confidence intervals? BMJ. 2013; 346:f3212 [AO,I]
PREGUNTA ESTADÍSTICA: ¿VALORES P O INTERVALOS DE CONFIANZA?
 
 
Fletcher J. Exemplary medicine: why doctors should practise what they preach. CMAJ. 2013; 185:635 [AO,I]
MEDICINA EJEMPLARIZANTE: ¿POR QUÉ LOS MÉDICOS DEBERÍAN PRACTICAR LO QUE PREDICAN?
 
Gardam M, Lemieux C. Mandatory influenza vaccination? First we need a better vaccine. CMAJ. 2013; 185:639-640 [AO,I]
¿VACUNA ANTIGRIPAL OBLIGATORIA? PRIMERO SE NECESITA UNA VACUNA MEJOR
 
Gandell D, Straus SE, Bundookwala M, Tsui V, Alibhai SM. Treatment of constipation in older people. CMAJ. 2013; 185:663-670 [R,I]
TRATAMIENTO DEL ESTREÑIMIENTO EN LAS PERSONAS MAYORES
 
Kuwert P, Pietrzak RH, Glaesmer H. Trauma and posttraumatic stress disorder in older adults. CMAJ. 2013; 185:685 [R,I]
TRAUMA Y TRASTORNO DE ESTRÉS POSTRAUMÁTICO EN ANCIANOS
 
Koskenkorva T, Koivunen P, Koskela M, Niemela O, Kristo A, Alho OP. Short-term outcomes of tonsillectomy in adult patients with recurrent pharyngitis: a randomized controlled trial. CMAJ. 2013; 185:E331-E336 [EC,II]
23549975             R/C
RESULTADOS A CORTO PLAZO DE LA TONSILECTOMÍA EN PACIENTES ADULTOS CON FARINGITIS RECURRENTE: ENSAYO CONTROLADO ALEATORIZADO
 
Young JW, Juurlink DN. Tramadol. CMAJ. 2013; 185:E352 [R,I]
TRAMADOL
 
 
Gold DR, Mittleman MA. New insights into pollution and the cardiovascular system: 2010 to 2012. Circulation. 2013; 127:1903-1913 [R,II]
NUEVAS REFLEXIONES SOBRE CONTAMINACIÓN Y SISTEMA CARDIOVASCULAR: 2010 A 2012
 
Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, et al. Management of patients with atrial fibrillation (Compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS Recommendations): a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 127:1916-1926 [M,III]
MANEJO DE PACIENTES CON FIBRILACIÓN AURICULAR (COMPILACIÓN DE LAS RECOMENDACIONES ACCF/AHA/ESC 2006 Y ACCF/AHA/HRS 2011): INFORME DEL ACC/AHA TASK FORCE SOBRE GUÍAS DE PRÁCTICA CLÍNICA
 
Jackson R, Kerr A, Wells S. Vascular risk calculators: essential but flawed clinical tools? Circulation. 2013; 127:1929-1931 [AO,I]
CALCULADORES DE RIESGO VASCULAR: ¿HERRAMIENTAS CLÍNICAS ESENCIALES PERO DEFECTUOSAS?
 
Allan GM, Nouri F, Korownyk C, Kolber MR, Vandermeer B, McCormack J. Agreement among cardiovascular disease risk calculators. Circulation. 2013; 127:1948-1956 [T,II]
23575355             R/C
CONCORDANCIA ENTRE LOS CALCULADORES DE RIESGO DE ENFERMEDAD CARDIOVASCULAR
 
Rutherford JD. Digital clubbing. Circulation. 2013; 127:1997-1999 [AO,I]
 
 
Arjona JC, Marre M, Barzilai N, Guo H, Golm GT, Sisk CM, et al. Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency. Diabetes Care. 2013; 36:1067-1073 [EC,I]
23248197             R/C
EFICACIA Y SEGURIDAD DE LA SITAGLIPTINA FRENTE A LA GLIPIZIDA EN PACIENTES CON DIABETES TIPO 2 E INSUFICIENCIA RENAL CRÓNICA DE MODERADA A GRAVE
 
Rubin RR, Peyrot M, Gaussoin SA, Espeland MA, Williamson D, Faulconbridge LF, et al; Look AHEAD Research Group. Four-year analysis of cardiovascular disease risk factors, depression symptoms, and antidepressant medicine use in the Look AHEAD (Action for Health in Diabetes) clinical trial of weight loss in diabetes. Diabetes Care. 2013; 36:1088-1094 [EC,II]
23359362             R/C
ANÁLISIS DE CUATRO AÑOS DE FACTORES DE RIESGO DE ENFERMEDAD CARDIOVASCULAR, SÍNTOMAS DE DEPRESIÓN Y USO DE MEDICAMENTOS ANTIDEPRESIVOS EN EL ENSAYO CLÍNICO LOOK AHEAD DE PÉRDIDA DE PESO EN LA DIABETES
 
Morrison F, Shubina M, Goldberg SI, Turchin A. Performance of primary care physicians and other providers on key process measures in the treatment of diabetes. Diabetes Care. 2013; 36:1147-1152 [S,II]
23230095             R/C
RENDIMIENTO DE LOS MÉDICOS DE ATENCIÓN PRIMARIA Y DE OTROS PROFESIONALES SOBRE MEDIDAS CLAVE DE PROCESO EN EL TRATAMIENTO DE LA DIABETES
 
Tanaka S, Tanaka S, Iimuro S, Yamashita H, Katayama S, Akanuma Y, et al; Japan Diabetes Complications Study Group and the Japanese Elderly Diabetes Intervention Trial Group. Predicting macro- and microvascular complications in type 2 diabetes: the Japan Diabetes Complications Study/the Japanese Elderly Diabetes Intervention Trial risk engine. Diabetes Care. 2013; 36:1193-1199 [M,II]
23404305             R/C
PREDECIR COMPLICACIONES MACRO Y MICROVASCULARES EN LA DIABETES TIPO 2: CALCULADOR DE RIESGO DEL JAPAN DIABETES COMPLICATIONS STUDY/THE JAPANESE ELDERLY DIABETES INTERVENTION TRIAL
 
Danaei G, García LA, Fernandez O, Hernán MA. Statins and risk of diabetes: an analysis of electronic medical records to evaluate possible bias due to differential survival. Diabetes Care. 2013; 36:1236-1240 [T,II]
23248196             R/C
ESTATINAS Y RIESGO DE DIABETES: ANÁLISIS DE LAS HISTORIAS CLÍNICAS ELECTRÓNICAS PARA EVALUAR POSIBLE SESGO DEBIDO A DIFERENCIAL DE SUPERVIVENCIA
 
Reis JP, Hankinson AL, Loria CM, Lewis CE, Powell-Wiley T, Wei GS, et al. Duration of abdominal obesity beginning in young adulthood and incident diabetes through middle age: the CARDIA study. Diabetes Care. 2013; 36:1241-1247 [S,II]
23248193             R/C
DURACIÓN DEL COMIENZO DE LA OBESIDAD ABDOMINAL EN LA JUVENTUD E INCIDENCIA DE DIABETES DURANTE LA EDAD MEDIANA: ESTUDIO CARDIA
 
Gerstein HC, Ambrosius WT, Danis R, Ismail-Beigi F, Cushman W, Calles J, et L; ACCORD Study Group. Diabetic retinopathy, its progression, and incident cardiovascular events in the ACCORD trial. Diabetes Care. 2013; 36:1266-1271 [EC,II]
23238658             R/C
RETINOPATÍA DIABÉTICA, SU PROGRESIÓN E INCIDENCIA DE ACONTECIMIENTOS CARDIOVASCULARES EN EL ENSAYO ACCORD
 
Jakicic JM, Egan CM, Fabricatore AN, Gaussoin SA, Glasser SP, Hesson LA, et al; Look AHEAD Research Group. Four-year change in cardiorespiratory fitness and influence on glycemic control in adults with type 2 diabetes in a randomized trial: the Look AHEAD trial. Diabetes Care. 2013; 36:1297-1303 [EC,II]
23223405             R/C
CAMBIO EN CUATRO AÑOS EN LA APTITUD CARDIORRESPIRATORIA E INFLUENCIA SOBRE EL CONTROL GLUCÉMICO EN ADULTOS CON DIABETES TIPO 2 EN UN ENSAYO ALEATORIZADO: ENSAYO LOOK AHEAD
 
Hong J, Zhang Y, Lai S, Lv A, Su Q, Dong Y, et al; SPREAD-DIMCAD Investigators. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care. 2013; 36:1304-1311 [EC,I]
23230096             R/C
EFECTOS DE LA METFORMINA FRENTE A LA GLIPIZIDA SOBRE LOS RESULTADOS CARDIOVASCULARES EN PACIENTES CON DIABETES TIPO 2 Y ENFERMEDAD ARTERIAL CORONARIA
 
Tsur A, Feldman BS, Feldhammer I, Hoshen MB, Leibowitz G, Balicer RD. Decreased serum concentrations of 25-hydroxycholecalciferol are associated with increased risk of progression to impaired fasting glucose and diabetes. Diabetes Care. 2013; 36:1361-1367 [S,I]
23393216             R/C
LAS CONCENTRACIONES SÉRICAS DISMINUIDAS DE 25-HIDROXICOLECALCIFEROL SE ASOCIAN CON AUMENTO DEL RIESGO DE PROGRESIÓN HACIA GLUCEMIA BASAL ALTERADA Y DIABETES
 
Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013; 36:1384-1395 [M,III]
23589542             R/C
HIPOGLUCEMIA Y DIABETES: INFORME DE UN GRUPO DE TRABAJO DE LA AMERICAN
DIABETES ASSOCIATION Y LA ENDOCRINE SOCIETY
 
Song Y, Wang L, Pittas AG, Del Gobbo LC, Zhang C, Manson JE, et al. Blood 25-hydroxy vitamin D levels and incident type 2 diabetes: a meta-analysis of prospective studies. Diabetes Care. 2013; 36:1422-1428 [M,II]
23613602             R/C
NIVELES SANGUÍNEOS DE 25-HIDROXI-VITAMINA D E INCIDENCIA DE DIABETES TIPO 2: METAANÁLISIS DE ESTUDIOS PROSPECTIVOS
 
Leal J, Hayes AJ, Gray AM, Holman RR, Clarke PM. Temporal validation of the UKPDS outcomes model using 10-year posttrial monitoring data. Diabetes Care. 2013; 36:1541-1546 [EC,II]
23275370             R/C
VALIDACIÓN TEMPORAL DEL MODELO DE RESULTADOS DEL UKPDS USANDO DATOS DE MONITORIZACIÓN POST-ENSAYO A LOS 10 AÑOS
 
Preis SR, Pencina MJ, Mann DM, D'Agostino RB Sr, Savage PJ, Fox CS. Early-adulthood cardiovascular disease risk factor profiles among individuals with and without diabetes in the Framingham Heart study. Diabetes Care. 2013; 36:1590-1596 [S,II]
23340887             R/C
PERFILES DE RIESGO DE ENFERMEDAD CARDIOVASCULAR EN LA VIDA ADULTA TEMPRANA ENTRE INDIVIDUOS CON Y SIN DIABETES EN EL ESTUDIO FRAMINGHAM HEART
 
Katon JG, Reiber GE, Nelson KM. Peripheral neuropathy defined by monofilament insensitivity and diabetes status: NHANES 1999-2004. Diabetes Care. 2013; 36:1604-1606 [T,II]
23275365             R/C
NEUROPATÍA PERIFÉRICA DEFINIDA POR LA INSENSIBILIDAD AL MONOFILAMENTO EN EL ESTADO DE DIABETES: NHANES 1999-2004
 
TODAY Study Group. Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: the TODAY clinical trial. Diabetes Care. 2013; 36:1735-1741 [EC,II]
23704672             R/C
RÁPIDO AUMENTO DE LA HIPERTENSIÓN Y LA NEFROPATÍA EN LOS JÓVENES CON DIABETES TIPO 2: ENSAYO CLÍNICO TODAY
 
Linder BL, Fradkin JE, Rodgers GP. The TODAY study: an NIH perspective on its implications for research. Diabetes Care. 2013; 36:1775-1776 [AO,I]
ESTUDIO TODAY: PERSPECTIVA DE LOS NIH SOBRE SUS IMPLICACIONES PARA LA INVESTIGACIÓN
 
 
Keating GM. Insulin degludec and insulin degludec/insulin aspart: a review of their use in the management of diabetes mellitus. Drugs. 2013; 73:575-593 [R,II]
INSULINA DEGLUDEC E INSULINA DEGLUDEC/INSULINA ASPART: REVISIÓN DE SU USO EN EL TRATAMIENTO DE LA DIABETES MELLITUS
 
Carter NJ, Plosker GL. Rivaroxaban: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Drugs. 2013; 73:715-739 [R,II]
RIVAROXABÁN: REVISIÓN DE SU USO EN LA PREVENCIÓN DEL ICTUS Y EL EMBOLISMO SISTÉMICO EN PACIENTES CON FIBRILACIÓN AURICULAR
 
Carter NJ. Inhaled glycopyrronium bromide: a review of its use in patients with moderate to severe chronic obstructive pulmonary disease. Drugs. 2013; 73:741-753 [R,II]
BROMURO DE GLUCOPIRRONIO INHALADO: REVISIÓN DE SU USO EN PACIENTES CON EPOC DE MODERADO A GRAVE
 
 
Chapman MJ, Giral P, Barter PJ. The conundrum of C-reactive protein as a risk marker for cardiovascular risk assessment: insight from EPIC-Norfolk and JUPITER. Eur Heart J. 2013; 34:1318-1320 [AO,I]
EL ENIGMA DE LA PROTEÍNA C REACTIVA COMO MARCADOR DE RIESGO EN LA VALORACIÓN DEL RIESGO CARDIOVASCULAR: REFLEXIÓN SOBRE EPIC-NORFOLK Y JUPITER
 
Sondermeijer BM, Boekholdt SM, Rana JS, Kastelein JJ, Wareham NJ, Khaw KT. Clinical implications of JUPITER in a contemporary European population: the EPIC-Norfolk prospective population study. Eur Heart J. 2013; 34:1350-1357 [S,II]
IMPLICACIONES CLÍNICAS DEL JUPITER EN UNA POBLACIÓN EUROPEA CONTEMPORÁNEA: ESTUDIO PROSPECTIVO DE POBLACIÓN EPIC-NORFOLK
 
Zittermann A, Kuhn J, Dreier J, Knabbe C, Gummert JF, Börgermann J. Vitamin D status and the risk of major adverse cardiac and cerebrovascular events in cardiac surgery. Eur Heart J. 2013; 34:1358-1364 [S,I]
ESTADO DE VITAMINA D Y RIESGO DE ACONTECIMIENTOS ADVERSOS IMPORTANTES CARDIACOS Y CEREBROVASCULARES EN CIRUGÍA CARDIACA
 
Tomson J, Emberson J, Hill M, Gordon A, Armitage J, Shipley M, et al. Vitamin D and risk of death from vascular and non-vascular causes in the Whitehall study and meta-analyses of 12 000 deaths. Eur Heart J. 2013; 34:1365-1374 [M,II]
VITAMINA D Y RIESGO DE MUERTE POR CAUSAS VASCULARES Y NO VASCULARES EN EL ESTUDIO WHITEHALL Y METAANÁLISIS DE 12.000 MUERTES
 
Braunwald E. Chronic heart failure: a look through the rear view mirror. Eur Heart J. 2013; 34:1391-1392 [AO,I]
INSUFICIENCIA CARDIACA CRÓNICA: MIRADA POR EL RETROVISOR
 
Pocock SJ, Ariti CA, McMurray JJ, Maggioni A, Køber L, Squire IB, et al; Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC). Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J. 2013; 34:1404-1413 [M,II]
PREDECIR LA SUPERVIVENCIA EN LA INSUFICIENCIA CARDIACA: TABLA DE RIESGO BASADA EN 39.372 PACIENTES DE 30 ESTUDIOS
 
van Veldhuisen DJ, Van Gelder IC, Ahmed A, Gheorghiade M. Digoxin for patients with atrial fibrillation and heart failure: paradise lost or not? Eur Heart J. 2013; 34:1468-1470 [AO,I]
DIGOXINA EN PACIENTES CON FIBRILACIÓN AURICULAR E INSUFICIENCIA CARDIACA: ¿PARAÍSO PERDIDO O NO?
 
Kirchhof P, Curtis AB, Skanes AC, Gillis AM, Samuel Wann L, John Camm A. Atrial fibrillation guidelines across the Atlantic: a comparison of the current recommendations of the European Society of Cardiology/European Heart Rhythm Association/European Association of Cardiothoracic Surgeons, the American College of Cardiology Foundation/American Heart Association/Heart Rhythm Society, and the Canadian Cardiovascular Society. Eur Heart J. 2013; 34:1471-1474 [M,III]
GUÍAS SOBRE FIBRILACIÓN AURICULAR A TRAVÉS DEL ATLÁNTICO: COMPARACIÓN DE LAS RECOMENDACIONES ACTUALES DE LAS EUROPEAN SOCIETY OF CARDIOLOGY/EUROPEAN HEART RHYTHM ASSOCIATION/EUROPEAN ASSOCIATION OF CARDIOTHORACIC SURGEONS, LAS AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION/AMERICAN HEART ASSOCIATION/HEART RHYTHM SOCIETY, Y LA CANADIAN CARDIOVASCULAR SOCIETY
 
Hijazi Z, Oldgren J, Siegbahn A, Granger CB, Wallentin L. Biomarkers in atrial fibrillation: a clinical review. Eur Heart. J 2013; 34:1475-1480 [R,I]
BIOMARCADORES EN LA FIBRILACIÓN AURICULAR: REVISIÓN CLÍNICA
 
Whitbeck MG, Charnigo RJ, Khairy P, Ziada K, Bailey AL, Zegarra MM, et al. Increased mortality among patients taking digoxin--analysis from the AFFIRM study. Eur Heart J. 2013; 34:1481-1488 [S,II]
AUMENTO DE MORTALIDAD ENTRE PACIENTES QUE TOMAN DIGOXINA-- ANÁLISIS DEL ESTUDIO AFFIRM
 
Gheorghiade M, Fonarow GC, van Veldhuisen DJ, Cleland JG, Butler J, Epstein AE, et al. Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J. 2013; 34:1489-1497 [S,II]
FALTA DE PRUEBAS DE AUMENTO DE MORTALIDAD ENTRE PACIENTES CON FIBRILACIÓN AURICULAR QUE TOMAN DIGOXINA: HALLAZGOS DEL ANÁLISIS EMPAREJADO DE TENDENCIA POST-HOC DEL ENSAYO AFFIRM
 
Connolly SJ, Eikelboom J, Dorian P, Hohnloser SH, Gretler DD, Sinha U, et al. Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa). Eur Heart J. 2013; 34:1498-1505 [EC,II]
BETRIXABAN COMPARADO CON WARFARINA EN PACIENTES CON FIBRILACIÓN AURICULAR: RESULTADOS DE UN ESTUDIO DE AMPLITUD DE DOSIS, ALEATORIZADO, EN FASE 2 (EXPLORE-XA)
 
 
Kruse RL, Olsberg JE, Oliver DP, Shigaki CL, Vetter-Smith MJ, Lemaster JW. Patient-provider communication about diabetes self-care activities. Fam Med. 2013; 45:319-322 [C,I]
COMUNICACIÓN ENTRE EL PACIENTE Y EL PROFESIONAL SOBRE LAS ACTIVIDADES DE AUTOCUIDADO EN LA DIABETES
 
Young RA, Bayles B, Benold TB, Hill JH, Kumar KA, Burge S. Family physicians' perceptions on how they deliver cost-effective care: a qualitative study from the Residency Research Network of Texas (RRNeT). Fam Med. 2013; 45:311-318 [C,I]
PERCEPCIONES DE LOS MÉDICOS DE FAMILIA DE CÓMO PROPORCIONAN UNA ATENCIÓN RENTABLE: ESTUDIO CUALITATIVO DE LA RRNeT
 
Dai H, Fang L, Malouin RA, Huang L, Yokosawa KE, Liu G. Family medicine training in China. Fam Med. 2013; 45:341-344 [R,I]
FORMACIÓN EN MEDICINA DE FAMILIA EN CHINA
 
Scherger J. The inherent cost-effectiveness of family physicians. Fam Med. 2013; 45:309-310 [AO,II]
LA RENTABILIDAD INHERENTE DE LOS MÉDICOS DE FAMILIA
 
 
Benavides FG, Ruiz-Forès N, Delclós J, Domingo-Salvany A. Consumo de alcohol y otras drogas en el medio laboral en España. Gac Sanit. 2013; 27:248-253 [T,I]
CONSUMO DE ALCOHOL Y OTRAS DROGAS EN EL MEDIO LABORAL EN ESPAÑA
 
Ortún V. Las encrucijadas de la atención primaria. Gac Sanit. 2013; 27:193-195 [AO,II]
LAS ENCRUCIJADAS DE LA ATENCIÓN PRIMARIA
 
Hoffmann R, Plug I, Khoshaba B, McKee M, Mackenbach JP; AMIEHS working group. Mortalidad tratable revisada: el estudio AMIEHS. Gac Sanit. 2013; 27:199-206 [T,II]
MORTALIDAD TRATABLE REVISADA: EL ESTUDIO AMIEHS
 
Román B, Ribas L, Ngo J, Serra L. Validación en población catalana del cuestionario internacional de actividad física. Gac Sanit. 2013; 27:254-257 [T,I]
VALIDACIÓN EN POBLACIÓN CATALANA DEL CUESTIONARIO INTERNACIONAL DE ACTIVIDAD FÍSICA
 
Fuentes-García A, Sánchez H, Lera L, Cea X, Albala C. Desigualdades socioeconómicas en el proceso de discapacidad en una cohorte de adultos mayores de Santiago de Chile. Gac Sanit. 2013; 27:226-232 [S,II]
DESIGUALDADES SOCIOECONÓMICAS EN EL PROCESO DE DISCAPACIDAD EN UNA COHORTE DE ADULTOS MAYORES DE SANTIAGO DE CHILE
 
Blanco A, Urbanos R, Thuissard IJ. Evolución de la prestación real media en España por edad y sexo (1998-2008) y su repercusión en las proyecciones de gasto sanitario público. Gac Sanit. 2013; 27:220-225 [CE,II]
EVOLUCIÓN DE LA PRESTACIÓN REAL MEDIA EN ESPAÑA POR EDAD Y SEXO (1998-2008) Y SU REPERCUSIÓN EN LAS PROYECCIONES DE GASTO SANITARIO PÚBLICO
 
Aller MB, Vargas I, Waibel S, Coderch-Lassaletta J, Sánchez-Pérez I, Llopart JR, et al. Factores asociados a la continuidad asistencial entre atención primaria y atención secundaria ambulatoria experimentada por los usuarios en el sistema de salud catalán. Gac Sanit. 2013; 27:207-213 [T,I]
FACTORES ASOCIADOS A LA CONTINUIDAD ASISTENCIAL ENTRE ATENCIÓN PRIMARIA Y ATENCIÓN SECUNDARIA AMBULATORIA EXPERIMENTADA POR LOS USUARIOS EN EL SISTEMA DE SALUD CATALÁN
 
 
Gossett DR, Kiley JW, Hammond C. Contraception is a fundamental primary care service. JAMA 2013;309:1997-1998 [AO,I]
LA ANTICONCEPCIÓN ES UN SERVICIO FUNDAMENTAL DE ATENCIÓN PRIMARIA
 
Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA. 2013; 309:2005-2015 [EC,I]
23644932             R/C
LUTEÍNA + ZEAXANTINA Y ÁCIDOS GRASOS OMEGA 3 EN LA DEGENERACIÓN MACULAR RELACIONADA CON LA EDAD: ENSAYO CLÍNICO ALEATORIZADO AREDS2
 
 
Widera E. What's to blame for falls and fractures? Poor sleep or the sleeping medication?: comment on "Nonbenzodiazepine sleep medication use and hip fractures in nursing home residents" JAMA Intern Med. 2013: 1-2 [Epub ahead of print] [AO,I]
¿A QUÉ HAY QUE ECHARLE LA CULPA DE LAS CAÍDAS Y FRACTURAS? ¿AL SUEÑO DE MALA CALIDAD O A LA MEDICACIÓN PARA DORMIR?: COMENTARIO SOBRE "USO DE MEDICACIÓN PARA DORMIR NO BENZODIAZEPÍNICA Y FRACTURAS DE CADERA EN RESIDENCIAS DE ANCIANOS"
 
Lautenschlager NT, Cox KL. Can participation in mental and physical activity protect cognition in old age? Comment on "The Mental Activity and eXercise (MAX) trial: a randomized controlled trial to enhance cognitive function in older adults" JAMA Intern Med. 2013: 1-2 [Epub ahead of print] [AO,I]
¿PUEDE LA PARTICIPACIÓN EN ACTIVIDADES MENTALES Y FÍSICAS PROTEGER LA COGNICIÓN EN LOS ANCIANOS? COMENTARIO SOBRE "ENSAYO MAX: ENSAYO CONTROLADO ALEATORIZADO PARA REFORZAR LA FUNCIÓN COGNITIVA EN ANCIANOS"
 
Berry SD, Lee Y, Cai S, Dore DD. Nonbenzodiazepine sleep medication use and hip fractures in nursing home residents. JAMA Intern Med. 2013:1-8 [Epub ahead of print][CC,I]
23460413             R/C
USO DE MEDICACIÓN PARA DORMIR NO BENZODIAZEPÍNICA Y FRACTURAS DE CADERA EN RESIDENCIAS DE ANCIANOS
 
Barnes DE, Santos-Modesitt W, Poelke G, Kramer AF, Castro C, Middleton LE, et al. The Mental Activity and eXercise (MAX) trial: a randomized controlled trial to enhance cognitive function in older adults. JAMA Intern Med. 2013: 1-8 [Epub ahead of print][EC,I]
23545598             R/C
ENSAYO MAX: ENSAYO CONTROLADO ALEATORIZADO PARA REFORZAR LA FUNCIÓN COGNITIVA EN ANCIANOS
 
Kerlikowske K, Zhu W, Hubbard RA, Geller B, Dittus K, Braithwaite D, et al; for the Breast Cancer Surveillance Consortium. Outcomes of screening mammography by frequency, breast density, and postmenopausal hormone therapy. JAMA Intern Med. 2013: 1-10 [Epub ahead of print][S,I]
23552817             R/C
RESULTADOS DE LA MAMOGRAFÍA DE CRIBAJE POR FRECUENCIA, DENSIDAD MAMARIA Y TERAPIA HORMONAL POSTMENOPÁUSICA
 
 
Cinciripini PM, Robinson JD, Karam-Hage M, Minnix JA, Lam C, Versace F, et al. Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal. JAMA Psychiatry. 2013; 70:522-533 [EC,I]
23536105             R/C
EFECTOS DEL USO DE LA VARENICLINA Y EL BUPROPION DE LIBERACIÓN SOSTENIDA MÁS CONSEJO INTENSIVO SOBRE ABANDONO TABÁQUICO SOBRE LA ABSTINENCIA TABÁQUICA PROLONGADA Y SOBRE LA DEPRESIÓN, AFECTIVIDAD NEGATIVA Y OTROS SÍNTOMAS DE LA RETIRADA DE LA NICOTINA
 
 
Pascual-Figal DA. Amplitud de distribución eritrocitaria, mucha más información con solo mirar el hemograma. Med Clin (Barc). 2013; 140:449-450 [AO,I]
AMPLITUD DE DISTRIBUCIÓN ERITROCITARIA, MUCHA MÁS INFORMACIÓN CON SOLO MIRAR EL HEMOGRAMA
 
Gómez-Vaquero C, Roig-Vilaseca D, Bianchi M, Santo P, Narváez J, Nolla JM. Evaluación de una propuesta de criterios de indicación de densitometría ósea en mujeres posmenopáusicas españolas basados en la herramienta FRAX ®. Med Clin (Barc). 2013; 140:439-443 [T,I]
EVALUACIÓN DE UNA PROPUESTA DE CRITERIOS DE INDICACIÓN DE DENSITOMETRÍA ÓSEA EN MUJERES POSMENOPÁUSICAS ESPAÑOLAS BASADOS EN LA HERRAMIENTA FRAX ®
 
Ruiz F, Castellano Mdel M, Aparisi F. Papel de la radiología intervencionista en el diagnóstico y tratamiento de la columna vertebral dolorosa. Med Clin (Barc). 2013; 140:458-465 [R,I]
PAPEL DE LA RADIOLOGÍA INTERVENCIONISTA EN EL DIAGNÓSTICO Y TRATAMIENTO DE LA COLUMNA VERTEBRAL DOLOROSA
 
Olivares M, Santas E, Miñana G, Palau P, Merlos P, Sanchis J et al. Amplitud de distribución eritrocitaria y riesgo de mortalidad en pacientes con insuficiencia cardiaca aguda. Med Clin (Barc). 2013; 140:433-438 [T,I]
AMPLITUD DE DISTRIBUCIÓN ERITROCITARIA Y RIESGO DE MORTALIDAD EN PACIENTES CON INSUFICIENCIA CARDIACA AGUDA
 
 
Hepatitis C in the USA and Europe: two problems, one solution. Lancet. 2013; 381:1688 [AO,I]
HEPATITIS C EN EE UU Y EUROPA: DOS PROBLEMAS, UNA SOLUCIÓN
 
Victora CG, Barros FC. Participatory women's groups: ready for prime time? Lancet. 2013; 381:1693-1694 [AO,I]
GRUPOS DE PARTICIPACIÓN DE MUJERES: ¿PREPARADOS PARA LA MÁXIMA AUDIENCIA?
 
Hawkes S, Buse K. Gender and global health: evidence, policy, and inconvenient truths. Lancet. 2013; 381:1783-1787 [AO,I]
GÉNERO SEXUAL Y SALUD MUNDIAL: EVIDENCIAS, POLÍTICA Y VERDADES INCONVENIENTES
 
 
Blumenthal D, Abrams MK. Putting aside preconceptions--time for dialogue among primary care clinicians. N Engl J Med. 2013; 368:1933-1934 [AO,I]
PONER A UN LADO LOS PREJUICIOS--HORA DE DIALOGAR ENTRE LOS CLÍNICOS DE ATENCIÓN PRIMARIA
 
Uyeki TM, Cox NJ. Global concerns regarding novel influenza A (H7N9) virus infections. N Engl J Med. 2013; 368:1862-1864 [AO,I]
PREOCUPACIONES MUNDIALES RESPECTO A LAS INFECCIONES POR EL NUEVO VIRUS DE LA GRIPE A (H7N9)
 
Frieden TR. Government's role in protecting health and safety. N Engl J Med. 2013; 368:1857-1859 [AO,I]
EL PAPEL DEL GOBIERNO EN LA PROTECCIÓN DE LA SALUD Y EN LA SEGURIDAD
 
Drenth JP. HCV treatment--no more room for interferonologists? N Engl J Med. 2013; 368:1931-1932 [AO,I]
TRATAMIENTO DEL VIRUS DE LA HEPATITIS C ¿YA NO HAY SITIO PARA LOS INTERFERONÓLOGOS?
 
Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med. 2013; 368:1888-1897 [T,II]
INFECCIÓN HUMANA CON UN NUEVO VIRUS DE LA GRIPE A (H7N9) DE ORIGEN AVIAR
 
Donelan K, DesRoches CM, Dittus RS, Buerhaus P. Perspectives of physicians and nurse practitioners on primary care practice. N Engl J Med. 2013; 368:1898-1906 [T,I]
PERSPECTIVAS DE MÉDICOS Y ENFERMERAS SOBRE LA PRÁCTICA DE LA ATENCIÓN PRIMARIA
 
Rosenthal MB, Mello MM. Sunlight as disinfectant--new rules on disclosure of industry payments to physicians. N Engl J Med. 2013; 368:2052-2054 [AO,I]
LA LUZ DEL SOL COMO DESINFECTANTE -- NUEVAS REGLAS SOBRE LA DIVULGACIÓN DE LOS PAGOS DE LA INDUSTRIA A LOS MÉDICOS
 
Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med. 2013; 368:1907-1917 [R,II]
TERAPIAS ACTUALES Y FUTURAS PARA LA INFECCIÓN POR EL VIRUS DE LA HEPATITIS C
 
Iglehart JK. Expanding the role of advanced nurse practitioners--risks and rewards. N Engl J Med. 2013; 368:1935-1941 [AO,I]
AMPLIAR EL PAPEL DE LAS ENFERMERAS AVANZADAS -- RIESGOS Y RECOMPENSAS
 
 
ANNALS OF INTERNAL MEDICINE
 
Primary care-feasible screening tools might help to identify some adults at increased risk for suicide but have limited ability to detect suicide risk in adolescents. Psychotherapy may reduce suicide attempts in some high-risk adults, but effective interventions for high-risk adolescents are not yet proven.
GUIDANCE STATEMENT 1: ACP recommends that clinicians inform men between the age of 50 and 69 years about the limited potential benefits and substantial harms of screening for prostate cancer. ACP recommends that clinicians base the decision to screen for prostate cancer using the prostate-specific antigen test on the risk for prostate cancer, a discussion of the benefits and harms of screening, the patient's general health and life expectancy, and patient preferences. ACP recommends that clinicians should not screen for prostate cancer using the prostate-specific antigen test in patients who do not express a clear preference for screening. GUIDANCE STATEMENT 2: ACP recommends that clinicians should not screen for prostate cancer using the prostate-specific antigen test in average-risk men under the age of 50 years, men over the age of 69 years, or men with a life expectancy of less than 10 to 15 years.
Since 2002, reports to FAERS of methadone-associated arrhythmia have increased substantially and are disproportionately represented relative to other events with the drug. Coadministration of methadone with antiretrovirals in patients with HIV may pose particular risk.
The USPSTF concludes that the current evidence is insufficient to assess the balance of the benefits and harms of combined vitamin D and calcium supplementation for the primary prevention of fractures in premenopausal women or in men. (I statement)The USPSTF concludes that the current evidence is insufficient to assess the balance of the benefits and harms of daily supplementation with greater than 400 IU of vitamin D3 and greater than 1000 mg of calcium for the primary prevention of fractures in noninstitutionalized postmenopausal women. (I statement)The USPSTF recommends against daily supplementation with 400 IU or less of vitamin D3 and 1000 mg or less of calcium for the primary prevention of fractures in noninstitutionalized postmenopausal women. (D recommendation).
Future RCTs of asymptomatic carotid artery stenosis should explore whether revascularization interventions provide benefit to patients treated by best-available medical therapy.
 
ATENCION PRIMARIA
 
A pesar de la elevada incidencia de incontinencia urinaria (IU) existe una escasa sensibilización de los profesionales sanitarios hacia esta afección, que no es grave, pero que sí autolimita de forma importante la vida de las personas que la presentan. Las sociedades científicas de Atención Primaria (Sociedad Española de Médicos de Atención Primaria [SEMERGEN], Sociedad Española de Médicos Generales y de Familia [SEMG], Sociedad Española de Medicina de Familia y Comunitaria [semFYC]) y la Asociación Española de Urología [AEU]) han elaborado este documento de consenso con los objetivos de sensibilizar al médico de atención primaria y ayudarle a la evaluación diagnóstica, tratamiento y derivación al especialista de la IU. El primer objetivo desde atención primaria (AP) debe ser la detección de la IU, por lo que se recomienda realizar un cribado oportunista al menos, una vez a lo largo de la vida en mujeres asintomáticas > 40 años y en varones asintomáticos > 55 años. En la evaluación diagnóstica, basada en la anamnesis y la exploración física, se deberá determinar el tipo y gravedad de la IU con el objetivo de derivar al especialista los casos de IU complicada. Con excepción de la vejiga hiperactiva (VH), el tratamiento conservador no farmacológico constituye el abordaje principal de la IU no complicada, tanto en mujeres como en varones. En la IU de urgencia/VH (IUU/VH), los antimuscarínicos son los únicos fármacos que han demostrado eficacia y seguridad. En el caso de los varones con síntomas mixtos, excluyendo los casos de obstrucción severa, se debe optar por un tratamiento combinado de alfa-bloqueantes y antimuscarínicos.
Uno de los problemas de nuestro sistema sanitario es el consumo inapropiado cuyas consecuencias más notorias son el despilfarro de recursos y la iatrogenia que no está justificada por la expectativa de ningún beneficio en términos de salud. Entre las posibles causas del consumo inadecuado se destaca la banalización de la medicina, que conlleva la pérdida de respeto y la ausencia de miramientos y por eso facilita cuando no estimula la temeridad en el consumo. Una temeridad de la que son responsables tanto pacientes como sanitarios y seguramente todavía más gestores y políticos. Sin una efectiva emancipación que lleve a los usuarios y ciudadanos a controlar los determinantes de su salud no parece posible disminuir el consumo inapropiado ni la iatrogenia asociada.
El gran número de inadecuaciones detectadas pone de manifiesto la importancia de evaluar la adecuación del tratamiento farmacológico en el paciente pluripatológico. Para ello es recomendable utilizar una estrategia de intervención farmacéutica combinada que incluya tanto un método implícito como un método explícito.
 
BRITISH JOURNAL OF PSYCHIATRY
 
Depressive symptoms and depressive illness are associated with impairments in sexual function and satisfaction but the findings of randomised placebo-controlled trials demonstrate that antidepressant drugs can be associated with the development or worsening of sexual dysfunction. Sexual difficulties during antidepressant treatment often resolve as depression lifts but may persist over long periods, and can reduce self-esteem and affect mood and relationships adversely. Sexual dysfunction during antidepressant treatment is typically associated with many possible causes, but the risk of dysfunction varies with differing antidepressants, and should be considered when selecting an antidepressant.
Dietary constituents have been increasingly researched as both potential aetiological factors and interventions for attention-deficit hyperactivity disorder (ADHD) symptoms. Although the involvement of dietary factors in ADHD is biologically plausible, the literature to date does not indicate causality and there are no grounds yet for the routine recommendation of dietary manipulation in ADHD.
The systematically derived spectrum of ethical issues in clinical dementia care presented in this paper can be used as training material for healthcare professionals, students and the public for raising awareness and understanding of the complexity of ethical issues in dementia care. It can also be used to identify ethical issues that should be addressed in dementia-specific training programmes, national strategy plans and clinical practice guidelines. Further research should evaluate whether this new genre of systematic reviews can be applied to the identification of ethical issues in other cognitive and somatic diseases. Also, the practical challenges in addressing ethical issues in training material, guidelines and policies need to be evaluated.
This study is the first to explore the benefit of treating asymptomatic or mildly symptomatic men with an enlarged prostate. Dutasteride significantly decreased the incidence of benign prostatic hyperplasia clinical progression.
The application of age adjusted cut-off values for D-dimer tests substantially increases specificity without modifying sensitivity, thereby improving the clinical utility of D-dimer testing in patients aged 50 or more with a non-high clinical probability.
The increased incidence of cancer after CT scan exposure in this cohort was mostly due to irradiation. Because the cancer excess was still continuing at the end of follow-up, the eventual lifetime risk from CT scans cannot yet be determined. Radiation doses from contemporary CT scans are likely to be lower than those in 1985-2005, but some increase in cancer risk is still likely from current scans. Future CT scans should be limited to situations where there is a definite clinical indication, with every scan optimised to provide a diagnostic CT image at the lowest possible radiation dose.
Sitagliptin use was not associated with an excess risk of all cause hospital admission or death compared with other glucose lowering agents among newly treated patients with type 2 diabetes. Most patients prescribed sitagliptin in this cohort were concordant with clinical practice guidelines, in that it was used as add-on treatment.
The research published to date suggests that cosmetic breast augmentation adversely affects the survival of women who are subsequently diagnosed as having breast cancer. These findings should be interpreted with caution, as some studies included in the meta-analysis on survival did not adjust for potential confounders. Further investigations are warranted regarding diagnosis and prognosis of breast cancer among women with breast implants.
QStroke provides a valid measure of absolute stroke risk in the general population of patients free of stroke or transient ischaemic attack as shown by its performance in a separate validation cohort. QStroke also shows some improvement on current risk scoring methods, CHADS2 and CHA2DS2VASc, for the subset of patients with atrial fibrillation for whom anticoagulation may be required. Further research is needed to evaluate the cost effectiveness of using these algorithms in primary care.
Compared with pravastatin, treatment with higher potency statins, especially atorvastatin and simvastatin, might be associated with an increased risk of new onset diabetes.
Measurement of PSA concentration in early midlife can identify a small group of men at increased risk of prostate cancer metastasis several decades later. Careful surveillance is warranted in these men. Given existing data on the risk of death by PSA concentration at age 60, these results suggest that three lifetime PSA tests (mid to late 40s, early 50s, and 60) are probably sufficient for at least half of men.
 
Conclusions Supported self monitoring by telemonitoring is an effective method for achieving clinically important reductions in blood pressure in patients with uncontrolled hypertension in primary care settings. However, it was associated with increase in use of National Health Service resources. Further research is required to determine if the reduction in blood pressure is maintained in the longer term and if the intervention is cost effective.
A clinical rule based on symptoms and signs to predict pneumonia in patients presenting to primary care with acute cough performed best in patients with mild or severe clinical presentation. Addition of CRP concentration at the optimal cut off of >30 mg/L improved diagnostic information, but measurement of procalcitonin concentration did not add clinically relevant information in this group.
Reductions in the rates of admissions to hospital for cycling related head injuries were greater in provinces with helmet legislation, but injury rates were already decreasing before the implementation of legislation and the rate of decline was not appreciably altered on introduction of legislation. While helmets reduce the risk of head injuries and we encourage their use, in the Canadian context of existing safety campaigns, improvements to the cycling infrastructure, and the passive uptake of helmets, the incremental contribution of provincial helmet legislation to reduce hospital admissions for head injuries seems to have been minimal.
An intervention to enhance self management support in routine primary care did not add noticeable value to existing care for long term conditions. The active components required for effective self management support need to be better understood, both within primary care and in patients' everyday lives.
 
CANADIAN MEDICAL ASSOCIATION JOURNAL
 
There was no significant difference in the number of episodes of severe pharyngitis between the control and treatment groups, and episodes were rare. However, tonsillectomy resulted in fewer symptoms of pharyngitis, consequently decreasing the number of medical visits and days absent from school or work. For this reason, surgery may benefit some patients
 
CIRCULATION
 
The decision as to which calculator to use for risk estimation has an important impact on both risk categorization and absolute risk estimates. This has broad implications for guidelines recommending therapies based on specific calculators.
 
DIABETES CARE
 
CVD risk factors are increased up to 30 years before diagnosis of diabetes. These findings highlight the importance of a life course approach to CVD risk factor identification among individuals at risk for diabetes.
Treatment with metformin for 3 years substantially reduced major cardiovascular events in a median follow-up of 5.0 years compared with glipizide. Our results indicated a potential benefit of metformin therapy on cardiovascular outcomes in high-risk patients.
In patients with T2DM and chronic renal insufficiency, sitagliptin and glipizide provided similar A1C-lowering efficacy. Sitagliptin was generally well-tolerated, with a lower risk of hypoglycemia and weight loss versus weight gain, relative to glipizide.
Aggressive monitoring of CVD risk in diabetic patients with depressive symptoms or who are treated with ADM may be warranted.
A 4-year ILI increased fitness and PA in overweight/obese individuals with T2DM. Change in fitness was associated with improvements in glycemic control, which provides support for interventions to improve fitness in adults with T2DM.
Our meta-analysis showed an inverse and significant association between circulating 25(OH)D levels and risk of type 2 diabetes across a broad range of blood 25(OH)D levels in diverse populations.
Vitamin D deficiency appears to be an independent risk factor for the development of IFG and diabetes.
Both the severity of retinopathy and its progression are determinants of incident CV outcomes. The retina may provide an anatomical index of the effect of metabolic and hemodynamic factors on future CV outcomes.
Longer duration of abdominal obesity was associated with substantially higher risk for diabetes independent of the degree of abdominal adiposity. Preventing or at least delaying the onset of abdominal obesity in young adulthood may lower the risk of developing diabetes through middle age.
Prevalence of hypertension and microalbuminuria increased over time among adolescents with type 2 diabetes regardless of diabetes treatment. The greatest risk for hypertension was male sex and higher BMI. The risk for microalbuminuria was more closely related to glycemic control.
In this sample of the general population, statin therapy was associated with 14% increased risk of type 2 diabetes. Differential survival did not explain this increased risk.
The UKPDS-OM has good predictive accuracy for two of four risk factor time paths and for 10-year clinical outcome probabilities with the exception of stroke, amputation, heart failure, and death from any cause. An updated version of the model incorporating PTM data is being developed.
The workgroup reconfirmed the previous definitions of hypoglycemia in diabetes, reviewed the implications of hypoglycemia on both short- and long-term outcomes, considered the implications of hypoglycemia on treatment outcomes, presented strategies to prevent hypoglycemia, and identified knowledge gaps that should be addressed by future research. In addition, tools for patients to report hypoglycemia at each visit and for clinicians to document counseling are provided.
PCPs provide better care through higher rates of medication intensification and lifestyle counseling. Covering physicians and midlevel providers may enable more frequent encounters when PCP resources are constrained.
Diabetes is associated with increased risk of peripheral neuropathy defined by monofilament insensitivity, but prediabetes and undiagnosed diabetes may be associated with only a modest increase in risk.
The risk engine accurately predicts macro- and microvascular complications and would provide helpful information in risk classification and health economic simulations.
 
DRUGS
 
Inhaled glycopyrronium bromide (Seebri(®) Breezhaler(®) capsules; NVA237) is a once-daily, long-acting muscarinic receptor antagonist (LAMA) that is approved in several countries, including the EU, as a maintenance bronchodilator for the symptomatic treatment of adult patients with chronic obstructive pulmonary disease (COPD). In the randomized, controlled, phase III GLOW (GLycopyrronium bromide in chronic Obstructive pulmonary disease airWays clinical study)-1 and -2 trials, treatment with inhaled glycopyrronium bromide 50 µg once daily was associated with significantly better lung function than placebo in patients with moderate to severe COPD in terms of the trough forced expiratory volume in one second (FEV1) at 12 weeks (primary endpoint). Significant between-group differences in trough FEV1 in favour of inhaled glycopyrronium bromide were maintained for up to 52 weeks. Dyspnoea scores, health status and exacerbation rates were also improved to a greater extent in the inhaled glycopyrronium bromide than placebo groups in these trials. In the randomized, controlled, phase III GLOW3 trial, inhaled glycopyrronium bromide was associated with a significantly longer exercise endurance time than placebo after 3 weeks' treatment in patients with moderate to severe COPD. The drug was generally well tolerated over the 26-week (GLOW1) or 52-week (GLOW2) study duration, and had a tolerability profile that was generally similar to that of tiotropium bromide. Serious adverse events were consistent with those expected in patients with moderate to severe COPD. In conclusion, inhaled glycopyrronium bromide is a once-daily LAMA that is an effective bronchodilator for use in the treatment of patients with moderate to severe COPD.
Insulin degludec (Tresiba(®)) is an ultra-long-acting insulin analogue that is also available as a coformulation with rapid-acting insulin aspart (insulin degludec/insulin aspart) [Ryzodeg(®)]. Insulin degludec has a flat, stable glucose-lowering profile with a duration of action of >42 h, and less within-patient day-to-day variability in glucose-lowering effect than the long-acting insulin analogue insulin glargine. In clinical trials, insulin degludec achieved similar glycaemic control to that seen with insulin glargine in patients with type 1 or 2 diabetes, but with a lower risk of nocturnal hypoglycaemia. In addition, trials examining a flexible dosing regimen of insulin degludec in patients with type 1 or 2 diabetes show the potential for adjusting the injection time, without compromising glycaemic control or safety. A 200 U/mL formulation of insulin degludec is also available for use in patients who require large volumes of basal insulin. Insulin degludec/insulin aspart was noninferior to the long-acting insulin analogue insulin detemir in patients with type 1 diabetes and has the potential to reduce the number of daily injections. Trial results also indicate that insulin degludec/insulin aspart may be an appropriate option for initiating insulin therapy in patients with type 2 diabetes inadequately controlled with oral antidiabetic drugs. Subcutaneous insulin degludec was generally well tolerated in patients with type 1 or 2 diabetes. In conclusion, insulin degludec and insulin degludec/insulin aspart represent a useful advance in the treatment of type 1 or 2 diabetes.
Rivaroxaban (Xarelto(®)), a direct factor Xa inhibitor, is approved for the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF) in Canada or those with nonvalvular AF (NVAF) in the EU, US and Japan. It is administered at a fixed oral dose and generally does not require routine monitoring of coagulation parameters. In the ROCKET AF trial in patients with NVAF and a moderate to high risk of stroke, oral rivaroxaban 20 mg once daily (15 mg once daily in patients with moderate renal impairment) was noninferior to oral dose-adjusted warfarin once daily in preventing primary endpoint events (i.e. stroke and systemic embolism) in the per-protocol population (primary noninferiority analysis) and superior in the on-treatment safety population (primary superiority analysis). Several ROCKET AF subgroup analyses indicated that the treatment effect of rivaroxaban was consistent across patient subgroups stratified according to baseline factors, including the presence or absence of previous stroke or transient ischaemic attack. Patients with moderate renal impairment receiving the reduced rivaroxaban dosage (15 mg once daily) showed a treatment effect consistent with that seen with rivaroxaban 20 mg once daily in patients with normal renal function. The tolerability profile of rivaroxaban was generally acceptable in ROCKET AF, with no significant difference between rivaroxaban and warfarin in the incidence of major or nonmajor clinically-relevant bleeding events (primary safety endpoint). In the Japanese ROCKET AF trial, rivaroxaban 15 mg once daily (10 mg once daily in patients with moderate renal impairment) was noninferior to oral dose-adjusted warfarin once daily in the incidence of major or nonmajor clinically-relevant bleeding (primary study outcome). Thus, rivaroxaban is a reasonable alternative to warfarin for the prevention of stroke and systemic embolism in patients with NVAF.
 
 
EUROPEAN HEART JOURNAL
 
Digoxin was associated with a significant increase in all-cause mortality in patients with AF after correcting for clinical characteristics and comorbidities, regardless of gender or of the presence or absence of HF. These findings call into question the widespread use of digoxin in patients with AF.
In patients with paroxysmal and persistent AF, we found no evidence of increased mortality or hospitalization in those taking digoxin as baseline initial therapy.
In patients with HF of both reduced and preserved EF, the influences of readily available predictors of mortality can be quantified in an integer score accessible by an easy-to-use website www.heartfailurerisk.org. The score has the potential for widespread implementation in a clinical setting.
Despite strong inverse and apparently independent associations of 25(OH)D with vascular and non-vascular mortality, causality remains uncertain. Large-scale randomized trials, using high doses of vitamin D, are required to assess the clinical relevance of these associations.
Deficient 25(OH)D levels are prevalent in cardiac surgical patients in Central Europe and are independently associated with the risk of MACCE. Further research should clarify the potential of vitamin D supplements in reducing cardiovascular risk in vitamin D-deficient patients and also the mechanisms leading to adverse effects on the cardiovascular system in the small group of patients with 25(OH)D levels >100 nmol/L.
Betrixaban was well tolerated and had similar or lower rates of bleeding compared with well-controlled warfarin in patients with AF at risk for stroke.
Assessment of atrial fibrillation (AF)-associated stroke risk is at present mainly based on clinical risk scores such as CHADS2 and CHA2DS2-VASc, although these scores provide only modest discrimination of risk for individual patients. Biomarkers derived from the blood may help refine risk assessment in AF for stroke outcomes and for mortality. Recent studies of biomarkers in AF have shown that they can substantially improve risk stratification. Cardiac biomarkers, such as troponin and natriuretic peptides, significantly improve risk stratification in addition to current clinical risk stratification models. Similar findings have recently been described for markers of renal function, coagulation, and inflammation in AF populations based on large randomized prospective clinical trials or large community-based cohorts. These new findings may enable development of novel tools to improve clinical risk assessment in AF. Biomarkers in AF may also improve the understanding of the pathophysiology of AF further as well as potentially elucidate novel treatment targets. This review will highlight novel associations of biomarkers and outcomes in AF as well as recent progress in the use of biomarkers for risk stratification.
In this European cohort, JUPITER-eligible individuals had significantly higher event rates compared with those with LDL-C <3.4 mmol/L/C-reactive protein <2 mg and LDL-C ≥3.4 mmol/L/C-reactive protein <2 mg/L. Application of the JUPITER criteria qualified almost one-fifth of the population for statin therapy that otherwise would not have qualified based on SCORE or ATP III criteria.
 
FAMILY MEDICINE
 
Patients with diabetes regularly discussed self-care activities during follow-up visits at family medicine clinics. Providers varied in their capacity to incorporate self-care planning into routine medical care for patients with diabetes. Interventions are needed that help improve goal-setting and documentation. Documentation of self-care discussions will be important for meeting Meaningful Use criteria.
Family physicians perceived that their approaches to patient care result in medical decision making priorities and care delivery processes that contribute to more cost-effective health care. These outcomes were achieved less by providing preventive services and strictly adhering to guidelines but rather by how they individualized the management of new symptoms and chronic conditions.
In 2010, six ministries of the Chinese government jointly issued a plan for building team-based primary care led by family physicians, prompting the creation of new models of family medicine training across the country. The purpose of this paper is to describe examples of existing family physician training models in China, to present advantages and disadvantages of the various models, and to present a specific model of family medicine residency training implemented at the Zhejiang University Medical School-affiliated Sir Run Run Shaw Hospital in collaboration with the Michigan State University-affiliated Genesys Regional Medical Center.
 
GACETA SANITARIA
 
Los usuarios perciben una continuidad asistencial, aunque identifican elementos de discontinuidad, explicados parcialmente por el área de salud y por algunos factores individuales. Su abordaje contribuiría a adecuar la atención a las necesidades de los pacientes.
La innovación del estudio AMIEHS es una aproximación rigurosa a la nueva concepción de la mortalidad tratable que incluye validación empírica. Para evaluar la calidad de los sistemas de salud en comparación con otros países sólo pueden usarse con éxito indicadores validados.
La versión corta del Cuestionario Internacional de Actividad Física en su adaptación al catalán muestra una validez aceptable para medir la actividad física total y el tiempo dedicado a realizar actividad física vigorosa. Puede utilizarse para medir la adherencia a las recomendaciones de actividad física en la población catalana.
Este estudio corrobora la estratificación social de la funcionalidad y de la muerte, sugiriendo que la edad no es un nivelador. En Latinoamérica, las políticas sociales deberían orientarse a reducir estas desigualdades, buscando prevenir la exposición a riesgos y compensar carencias (en particular entre los más pobres) para minimizar la transformación de un impedimento en limitación y de una limitación en discapacidad.
La evolución de la cantidad y de la calidad de los servicios sanitarios que consume cada persona es un factor importante en la evolución del gasto sanitario, que es necesario introducir en el cálculo de proyecciones.
Los usuarios perciben una continuidad asistencial, aunque identifican elementos de discontinuidad, explicados parcialmente por el área de salud y por algunos factores individuales. Su abordaje contribuiría a adecuar la atención a las necesidades de los pacientes.
 
JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
 
Addition of lutein + zeaxanthin, DHA + EPA, or both to the AREDS formulation in primary analyses did not further reduce risk of progression to advanced AMD. However, because of potential increased incidence of lung cancer in former smokers, lutein + zeaxanthin could be an appropriate carotenoid substitute in the AREDS formulation.
 
JAMA INTERNAL MEDICINE
 
The risk for hip fracture is elevated among nursing home residents using a nonbenzodiazepine hypnotic drug. New users and residents having mild to moderate cognitive impairment or requiring limited assistance with transfers may be most vulnerable to the use of these drugs. Caution should be exercised when prescribing sleep medications to nursing home residents.
Women aged 50 to 74 years, even those with high breast density or HT use, who undergo biennial screening mammography have similar risk of advanced-stage disease and lower cumulative risk of false-positive results than those who undergo annual mammography. When deciding whether to undergo mammography, women aged 40 to 49 years who have extremely dense breasts should be informed that annual mammography may minimize their risk of advanced-stage disease but the cumulative risk of false-positive results is high
In inactive older adults with cognitive complaints, 12 weeks of physical plus mental activity was associated with significant improvements in global cognitive function with no evidence of difference between intervention and active control groups. These findings may reflect practice effects or may suggest that the amount of activity is more important than the type in this subject population. TRIAL REGISTRATION clinicaltrials.gov Identifier:NCT00522899.
 
JAMA PSYCHIATRY
 
In a community sample, varenicline exerts a robust and favorable effect on smoking cessation relative to placebo and may have a favorable (suppressive) effect on symptoms of depression and other affective measures, with no clear unfavorable effect on neuropsychiatric adverse events.
 
 
MEDICINA CLINICA
 
La aplicación de una propuesta de criterios de indicación de densitometría ósea en mujeres posmenopáusicas basada en la edad y en el riesgo de fractura calculado por FRAX® tendría como consecuencia una disminución significativa de la actividad de la unidad de densitometría ósea.
En este artículo se realiza una revisión general de los diferentes procedimientos intervencionistas percutáneos, guiados mediante técnicas de imagen, y utilizados para el diagnóstico y tratamiento de las diversas causas responsables del dolor de raquis. Estos procedimientos pueden ser meramente diagnósticos, como la discografía y la biopsia, diagnósticos y terapéuticos, como las infiltraciones, o puramente terapéuticos, como la vertebroplastia, las técnicas descompresivas del disco intervertebral o la ablación tumoral. Se revisan las indicaciones, ventajas y complicaciones de las diferentes técnicas.
En pacientes con ICA los valores elevados del ADE se asocian a una mayor mortalidad a largo plazo.
 
THE NEW ENGLAND JOURNAL OF MEDICINE
 
Novel reassortant H7N9 viruses were associated with severe and fatal respiratory disease in three patients
Current policy recommendations that are aimed at expanding the supply and scope of practice of primary care nurse practitioners are controversial. Physicians and nurse practitioners do not agree about their respective roles in the delivery of primary care
 
 
 

 

 

                      

XXVIII Congreso de Comunicación y Salud

 

 

semFYC - JRT 2017

 

Cáceres, 10 y 11 de Noviembre 2017


____________________________

 Para pacientes
@pontealdiaAP
 @pontealdiaURG
55 e.SAMFyC

 


 

semFYC
 

 

Estadisticas

Ver contenido por hits : 1101601



La SAMFyC:
 C/ Arriola, 4, bajo D, CP.18001 - Granada. Email: samfyc@samfyc.es; Teléfono: 958 804 201 - Fax: 958 804 202. Horario de invierno: lunes a jueves de 9:00 a 17:30 horas; viernes de 9:00 a 14:30 horas. Horario de verano: lunes a viernes de 8:00 a 15:00h. Todos los derechos reservados. Aviso Legal. 


¡CSS Válido!

Diseño web